In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...